Menu

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]

Cytokinetics and Astellas Pharma Join Forces to Fight Muscle Disease

Cytokinetics, Inc., the San Francisco-based company currently conducting a Phase II ALS clinical trial of the fast skeletal troponin muscle activator tirasemtiv, has signed a $490 million collaboration with Astellas Pharma, Inc. The two companies will be working together to develop new skeletal muscle activators, with Astellas Pharma focusing on non-neuromuscular indications and Cytokinetics focusing on neuromuscular targets including ALS. Unfortunately, the Phase II tirasemtiv trial had a recent setback due to a computer programming error that resulted in 58 patients receiving placebo instead of the study drug, but Cytokinetics has corrected the error and the trial is back on track.

Cytokinetics, Inc., the San Francisco-based company currently conducting a Phase II ALS clinical trial of the fast skeletal troponin muscle activator tirasemtiv, has signed a $490 million collaboration with Astellas Pharma, Inc. The two companies will be working together to develop new skeletal muscle activators, with Astellas Pharma focusing on non-neuromuscular indications and Cytokinetics focusing on neuromuscular targets including ALS. Unfortunately, the Phase II tirasemtiv trial had a recent setback due to a computer programming error that resulted in 58 patients receiving placebo instead of the study drug, but Cytokinetics has corrected the error and the trial is back on track.

Post navigation

Filter articles published since 2015 by topic, disease, or article type.

Guidlines for filtering

Results are filtered to show all matching articles from a particular category, and to show only articles that match all selected categories.

For instance, if "Biomarkers" and "Genetics" are selected in the Topic category, and "Multiple sclerosis" is selected in the Disease category, all results that match EITHER the Biomarkers OR Genetics Topic category will be shown, but only if they also match the Multiple sclerosis Disease category; i.e. Boolean search of [("Biomarkers" OR "Genetics") AND "multiple sclerosis"]